Defence Therapeutics Inc. (DTCFF)

Compare

0.7500

0.0000

(0.00%)

At close: January 31 at 3:00:00 PM EST

Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million

Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce the closing of the 2nd tranche of its previously announced non-brokered private placement (the "Offering") of units of the Company (t

Newsfile 16 hours ago

DTCFF
0.00%
Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025

Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce its participation to the Biotech ShowcaseTM conference next week in San Francisco during the J.P. Morgan Healthcare Conference to meet

Newsfile 21 days ago

DTCFF
0.00%
Defence Fortifies Patent Portfolio

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce the further strengthening of its patent portfolio with several key patent issuances and allowances in multiple jurisdiction

Newsfile 26 days ago

DTCFF
0.00%
Defence Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - December 31, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce a non-brokered private placement of up to $4.2 million at $0.60 per unit comprising of up to seven million units (each, a

Newsfile last month

DTCFF
0.00%
Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Elias Theodorou has joined the board of directors, effective immediately.Dr. Elias Theodorou, Ph.D., is a molecu

Newsfile last month

DTCFF
0.00%
Defence Provides Update on Delivery of AGSM Proxy Materials

Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is to hold its annual general and special meeting of the shareholders (the "Shareholders") of the Company on December 12th, 2024 at 10:00 a.m. (P

Newsfile last month

DTCFF
0.00%
Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)

Vancouver, British Columbia--(Newsfile Corp. - November 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce its plan to license its proprietary Accum® technology to pharma and biotech companies developing Antibody Drug Conjugates

Newsfile 2 months ago

DTCFF
0.00%
Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development

Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Maxime Parisotto has joined the Company as Chief Scientific Officer, Director of Science and Business Developmen

Newsfile 2 months ago

DTCFF
0.00%
Defence Announces Closing of Securities for Debenture Financing

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it has closed its offering of unsecured convertible debentures (the "New Debentures") for aggregate gross proceeds of CAD$1,476,0

Newsfile 2 months ago

DTCFF
0.00%
Defence Therapeutics Announces Securities for Debenture Financing

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it offers new unsecured convertible debentures (the "New Debentures") for aggregate gross proceeds of up to CAD$1,570,000 (the "O

Newsfile 2 months ago

DTCFF
0.00%
Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors

Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Svetlana Selivanova has joined the board of directors, effective immediately. Dr. Svetlana Selivanova is radioch

Newsfile 2 months ago

DTCFF
0.00%
Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs

Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that it has received a 30-day extension approval from Canadian Securities Exchange to extend the closing for the balance o

Newsfile 2 months ago

DTCFF
0.00%
Defence Therapeutics Completes 1st Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of the 1st tranche of its previously announced non-brokered private placement (the "Offering") of units of the Company (the "Units") at a price of $0.50 per Unit for agg

Newsfile 3 months ago

DTCFF
0.00%
Defence's Corporate Updates, Arranges Financing

Vancouver, British Columbia--(Newsfile Corp. - September 27, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to give a corporate update and to announce a financing.The Company wishes to announce that Mr. Sebastien Plouffe, Defence's Founder and Director, is stepping back-in as the Chief Executive Of

Newsfile 4 months ago

DTCFF
0.00%
Defence Appoints New Interim Chief Executive Officer

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), announces that Kwin Grauer has been appointed interim Chief Executive Officer replacing Sébastien Plouffe as President and Chief Executive Officer. This change comes as the Company moves from the preclinical stage toward a clinical stage.Mr. Grauer joined the Board of Directors of the Company in December, 2022. He is a ...

Newsfile 4 months ago

DTCFF
0.00%
Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce a project consisting of investigating the potential benefit of using the Accum® technology to increase the half-life and efficacity of the GLP-1 agonist as a treatment for obesity and related comorbidities (

Newsfile 5 months ago

DTCFF
0.00%
Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances

Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to give an update on its Orano Support SAS partnership in the radiopharmaceuticals field, on behalf of Orano SAS ("Orano"), a world-renowned multinational nuclear company, headquartered in France.Defence is developing in

Newsfile 5 months ago

DTCFF
0.00%
Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program

Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its Canadian Nuclear Research Initiative Health ("CNRI-H") Program application was retained and approved by the Canadian Nuclear Laboratories ("CNL") to accelerate Defence's radio-immuno-conjugates projec

Newsfile 6 months ago

DTCFF
0.00%
Defence Receives No Objection Letter From Health Canada for Phase I Trial of Its Accum-002 (Accutox) as an Anti-Cancer Molecule in Patients With Melanoma

VANCOUVER, BC - (NewMediaWire) - July 8, 2024 - Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies,...

NewMediaWire 6 months ago

DTCFF
0.00%
Defence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors

Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that Defence's Accum-002TM ("AccuTOX®") has different mode of actions: AccuTOX® is working as a tumor killing molecule and as an immune booster. AccuTOX® mode of action synergizes with the activity of Immune Ch

Newsfile 7 months ago

DTCFF
0.00%

Performance Overview

Return	DTCFF	S&P/TSX Composite index
YTD	+92.26%	+3.71%
1-Year	-56.85%	+20.28%
3-Year	-81.48%	+23.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Defence Therapeutics Inc. (DTCFF)

Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million

Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025

Defence Fortifies Patent Portfolio

Defence Arranges Financing

Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors

Defence Provides Update on Delivery of AGSM Proxy Materials

Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC)

Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development

Defence Announces Closing of Securities for Debenture Financing

Defence Therapeutics Announces Securities for Debenture Financing

Defence Announces Radiopharmaceutical Expert Svetlana Selivanova Joins Board of Directors

Defence Announces Extension of Private Placement, Continues Development of Its Radiopharmaceuticals and ADC Programs

Defence Therapeutics Completes 1st Tranche of Financing

Defence's Corporate Updates, Arranges Financing

Defence Appoints New Interim Chief Executive Officer

Defence Investigates the Application of the Accum Hydrogel Technology to Deliver GLP-1 in Order to Increase the Treatment Efficacy of Diabetes and Weight Loss

Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances

Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program

Defence Receives No Objection Letter From Health Canada for Phase I Trial of Its Accum-002 (Accutox) as an Anti-Cancer Molecule in Patients With Melanoma

Defence's AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors

Performance Overview